US 12,102,625 B2
Solid forms of FXR agonists
Derek M. Dalton, Berkeley, CA (US); Peter C. Fung, San Mateo, CA (US); Nolan Griggs, San Mateo, CA (US); Jeffrey N. Hemenway, San Mateo, CA (US); Olga V. Lapina, Newark, CA (US); Matthew M. Logan, San Mateo, CA (US); Sean T. Neville, San Mateo, CA (US); Bryan J. Reynolds, Chicago, IL (US); Hui-Wen Shih, San Mateo, CA (US); and Anna M. Wagner, Hayward, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Oct. 31, 2022, as Appl. No. 18/051,471.
Application 18/051,471 is a division of application No. 16/791,974, filed on Feb. 14, 2020, granted, now 11,524,005.
Claims priority of provisional application 62/807,542, filed on Feb. 19, 2019.
Prior Publication US 2023/0190721 A1, Jun. 22, 2023
Int. Cl. A61K 31/4439 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01)
CPC A61K 31/4439 (2013.01) [C07D 401/14 (2013.01); C07D 413/14 (2013.01)] 27 Claims
 
1. A solid form of a compound of the following formula:

OG Complex Work Unit Chemistry
wherein the solid form is zwitterion Form I characterized by an X-ray diffraction pattern having 2θ-reflections at 6.7, 13.3, and 16.6 degrees 2θ, plus or minus 0.2 degrees 2θ;
wherein the solid form is zwitterion Form II characterized by an X-ray diffraction pattern having 2θ-reflections at 7.3, 18.1, and 24.1 degrees 2θ, plus or minus 0.2 degrees 2θ;
wherein the solid form is a zwitterionic hydrate characterized by an X-ray diffraction pattern having 2θ-reflections at 10.2, 15.4, 19.7, and 23.1 degrees 2θ, plus or minus 0.2 degrees 2θ; or
wherein the solid form is amorphous, having an X-ray diffraction pattern substantially as shown in FIG. 10.